WUXI06:BKK
Wuxi Biologics (Cayman) Inc. KKPS DR
5,20 THB
0,00%
(0,00) 1 pv
15.10., 16.40.00 UTC+7 · THB
search
Kaikki symbolit
| Symboli | Hinta | Muutos | Muutos (%) |
|---|
insights_autoLuodaan huippuvinkkejä: WUXI06…
Avaa
5,25 THB
Korkea
5,35 THB
Matala
5,05 THB
Markkina-arvo
200,24 mrd.
Keskimääräinen volyymi
93,60 t.
Volyymi
288,50 t.
52 viikon ylin
6,25 THB
52 viikon alin
3,02 THB
Liikkeellä olevat osakkeet
4,12 mrd.
Työntekijöiden lukumäärä
15 t.
Avaa
5,25 THB
Korkea
5,35 THB
Matala
5,05 THB
Markkina-arvo
200,24 mrd.
Keskimääräinen volyymi
93,60 t.
Volyymi
288,50 t.
52 viikon ylin
6,25 THB
52 viikon alin
3,02 THB
Liikkeellä olevat osakkeet
4,12 mrd.
Työntekijöiden lukumäärä
15 t.
Uutiset
Verkkolähteistä ja uutiskumppaneilta
Investor's Business Daily
·
17 minuuttia sitten
Futures Fall After Wild Day; Tesla Roadster On Tap
Yahoo Finance
·
1 tunti sitten
Grayscale Says Bitcoin’s Volatility Falls to 43%, Now Within S&P 500 Range
Moomoo
·
1 tunti sitten
Dow Jones Top Company Headlines at 7 PM ET: Netflix Replaces Content Chief as It Struggles to Engage Viewers | Tesla's ...
Bloomberg.com
·
2 tuntia sitten
Asian Stocks Set for Gains as Tech Selloff Eases: Markets Wrap
Profiili
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Tietoa: Wuxi Biologics (Cayman) Inc. KKPS DR
ToimitusjohtajaZhisheng Chen
Työntekijät14,7 t.
Perustamispäivä2010
Päätoimipaikka-
Toimiala-
Sivustowuxibiologics.com